Dark

Check out our Dark Pool Levels

ALIM
Alimera Sciences, Inc.
stock NASDAQ

Inactive

Sep 13, 2024

5.54USD-0.180%(-0.01)2,679,904

Pre-market

0.00USD-100.000%(-5.55)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 5, 2022

08:00AM EST Alimera Sciences to Participate in Upcoming January 2022 Investor GlobeNewswire Inc

Dec 1, 2021

07:30AM EST Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin GlobeNewswire Inc

Nov 9, 2021

01:17PM EST Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Rick Eiswirth, Alimeras President and Chief Executive Officer, will participate in three investor conference events in November. GlobeNewswire Inc

Nov 5, 2021

11:03AM EDT Alimera Sciences, Inc. (ALIM) shares are adding more than 22 percent on Friday morning trade, continuing a bullish trend since November 2. There were no corporate announcements on the day to impact the stock movement. RTTNews

09:36AM EDT Alimera Sciences CEO Richard Eiswirth Reported Purchase of 28,005 Shares @ Avg Price of $4.45/Share in Form 4 Filing on Thursday Benzinga

Oct 28, 2021

08:26AM EDT The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug Benzinga

07:58AM EDT Alimera Sciences Q3 EPS $(0.60) Misses $(0.52) Estimate, Sales $12.15M Miss $12.37M Estimate Benzinga

07:30AM EDT -- Consolidated Net Revenue of $12.2 Million Down 2% vs. Third Quarter of 2020 andUp 14% vs. Second Quarter of 2021 -- U.S. End User Demand up 15% vs. Third Quarter of 2020 and Second Quarter of 2021 GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For October 28, 2021 Benzinga

Oct 25, 2021

11:11AM EDT EXCLUSIVE: Alimera Sciences CEO, Rick Eiswirth To Appear On Benzinga's 'Power Hour' At 12:45 p.m. ET Benzinga

Oct 24, 2021

11:45AM EDT The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More Benzinga

Oct 21, 2021

08:00AM EDT Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and to maintain better vision longer, announces today that it will report third quarter 2021 financial results on Thursday, October 28, 2021, prior to the market open. GlobeNewswire Inc

Oct 13, 2021

01:38PM EDT Alimera Sciences Highlights Data Presentation Of ILUVIEN For Patients With Diabetic Macular Edema At American Society Of Retina Specialists Benzinga

08:00AM EDT PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to Pre-ILUVIEN GlobeNewswire Inc

Sep 29, 2021

10:51AM EDT From BZ's Small Cap Healthcare Conference: Alimera Sciences CEO Rick Eiswirth Says Highlights 'New Day' Study Assessing ILUVIEN As Baseline Therapy In Patients With Early Diabetic Macular Edema Benzinga

10:48AM EDT From BZ's Small Cap Healthcare Conference: Alimera Sciences CEO Rick Eiswirth Says Generated ~$20M In Cash From China Expansion Deal, Eligible For Up To $89M In Milestones Benzinga

10:47AM EDT From BZ's Small Cap Healthcare Conference: Alimera Sciences CEO Rick Eiswirth Says In Process Of Launching Products Directly In Nordic Countries In Coming Months Benzinga

10:45AM EDT From BZ's Small Cap Healthcare Conference: Alimera Sciences CEO Rick Eiswirth Says Thinks There Is New Opportunity For Continued Organic Growth By Getting New Physicians To Use ILUVIEN Benzinga

10:33AM EDT From BZ's Small Cap Healthcare Conference: Alimera Sciences CEO Rick Eiswirth Begins Speaking Benzinga

Sep 2, 2021

04:34PM EDT Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd GlobeNewswire Inc

Aug 24, 2021

08:00AM EDT Alimera Sciences Announces National Pricing and Reimbursement GlobeNewswire Inc

Aug 16, 2021

10:10AM EDT HC Wainwright & Co. Maintains Buy on Alimera Sciences, Lowers Price Target to $12 Benzinga

Aug 13, 2021

09:41AM EDT Recap: Alimera Sciences Q2 Earnings Benzinga

08:06AM EDT Alimera Sciences Q2 EPS $1.03 Misses $1.06 Estimate, Sales $21.70M Beat $16.04M Estimate Benzinga

08:00AM EDT -- Consolidated Net Revenue of $21.7 Million up 117% vs. Second Quarter of 2020 -- Consolidated Net Product Revenue of $10.7 Million up 7% vs. Second Quarter of 2020 -- Net Income of $7.6 Million vs. Net Loss of $2.5 Million in Second Quarter of 2020 -- End User Demand up 16% on a Same Country Basis vs. Second Quarter of 2020 GlobeNewswire Inc

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

04:12AM EDT Earnings Scheduled For August 13, 2021 Benzinga

Aug 11, 2021

07:13AM EDT How Does Alimera Sciences's Debt Look? Benzinga

Aug 10, 2021

08:00AM EDT Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces today that it will report second quarter 2021 financial results on Friday, August 13, 2021, prior to the market open. GlobeNewswire Inc

Aug 9, 2021

08:12AM EDT Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN Benzinga

08:00AM EDT Alimera Sciences and Tanner Pharma Group Initiate Global Named GlobeNewswire Inc

May 27, 2021

08:15AM EDT Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 June 4, 2021. GlobeNewswire Inc

May 17, 2021

08:22AM EDT Alimera Sciences Appoints David Dyer As Chief Retina Specialist RTTNews

08:12AM EDT Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist GlobeNewswire Inc

Apr 29, 2021

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

Apr 28, 2021

05:04PM EDT Recap: Alimera Sciences Q1 Earnings Benzinga

05:03PM EDT Alimera Sciences Q1 EPS $(0.63) Misses $(0.54) Estimate, Sales $11.21M Miss $12.07M Estimate Benzinga

07:26AM EDT The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping Benzinga

04:15AM EDT Earnings Scheduled For April 28, 2021 Benzinga

Apr 27, 2021

10:28AM EDT Earnings Outlook For Alimera Sciences Benzinga

Apr 24, 2021

09:24AM EDT The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx Benzinga

Apr 22, 2021

08:00AM EDT Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces today that it will report first quarter 2021 financial results on Wednesday, April 28, 2021 after the market close. GlobeNewswire Inc

Apr 15, 2021

07:48AM EDT 10 Biggest Price Target Changes For Thursday Benzinga

07:01AM EDT HC Wainwright & Co. Maintains Buy on Alimera Sciences, Raises Price Target to $16 Benzinga

Apr 14, 2021

10:35AM EDT Alimera, Ocumension Ink Licensing Pact For Fluocinolone Acetonide Eye Implant In China Benzinga

09:03AM EDT Alimera Sciences Shares To Resume Trade At 9:20 a.m. EDT Benzinga

09:01AM EDT Alimera Sciences Reports Received $20M From Ocumension Therapeutics Benzinga

09:00AM EDT -- Alimera grants exclusive license to Ocumension for a $10 million upfront payment and up to $89 million in additional sales-based milestone payments -- Ocumension makes a$10 million equity investment in Alimera GlobeNewswire Inc

08:26AM EDT Alimera Sciences Shares Halted On Code News Pending Benzinga

Apr 9, 2021

08:00AM EDT Alimera Sciences to Present at the Zooming with LD Micro Virtual GlobeNewswire Inc

Mar 26, 2021

04:39PM EDT Highlights From Day 2 Of Benzinga's Biotech Small Cap Conference Benzinga

Mar 25, 2021

12:20PM EDT From BZ Biotech Conference: Alimera Sciences CEO Rick Eiswirth Says New Day Study To Assess ILUVIEN As First Line Therapy In Diabetic Macular Edema, Will Assess Effects Of Patient Reported Outcomes Benzinga

12:17PM EDT From BZ Biotech Conference: Alimera Sciences CEO Rick Eiswirth Says Looking To Launch In Nordic Countries This Year; Highlights Partnerships In Europe, Australia And Canada Benzinga

12:16PM EDT From BZ Biotech Conference: Alimera Sciences CEO Rick Eiswirth Says Working To Get More Physicians To Use ILUVIEN, Hopes To Be Able To Grow To Being Available In 16-18 Countries Benzinga

12:14PM EDT From BZ Biotech Conference: Alimera Sciences CEO Rick Eiswirth Says ILUVIEN Can Help Treat DME More Consistently, Reduces Recurrence Of Disease Benzinga

12:13PM EDT From BZ Biotech Conference: Alimera Sciences CEO Rick Eiswirth Says ILUVIEN Can Help Treat Disease More Consistently, Reduces Recurrence Of Disease Benzinga

11:53AM EDT From BZ Biotech Conference: Alimera Sciences CEO Rick Eiswirth Benzinga

Mar 18, 2021

08:00AM EDT Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announced today that President and CEO Rick Eiswirth will participate in the Benzinga Biotech Small Cap Conference to be held March 24-25, 2021. GlobeNewswire Inc

Mar 17, 2021

08:16AM EDT Alimera Sciences Says Achieves Extended Reimbursement In Ireland Benzinga

08:00AM EDT Alimera Sciences Continues to Execute on Its Expansion Strategy in GlobeNewswire Inc

Mar 11, 2021

08:00AM EST Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at Maxim Groups Inaugural Emerging Growth Virtual Conference to be held March 17-18, 2021. GlobeNewswire Inc

Feb 24, 2021

04:33PM EST Alimera Sciences Q4 EPS $(0.18) Misses $(0.04) Estimate, Sales $13.80M Beat $13.43M Estimate Benzinga

04:05PM EST Alimera Sciences Reports Fourth Quarter and 2020 Results GlobeNewswire Inc

07:30AM EST The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO Benzinga

03:35AM EST Earnings Scheduled For February 24, 2021 Benzinga

Feb 18, 2021

08:30AM EST Alimera Sciences Continues Global Geographic Expansion With Launch GlobeNewswire Inc

Feb 17, 2021

08:30AM EST Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces today that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021 after the market close. GlobeNewswire Inc

Feb 15, 2021

08:30AM EST Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the Microcap Rodeo Winter Wonderland Conference, which will be held from February 16-19, 2021. GlobeNewswire Inc

Jan 22, 2021

07:22AM EST The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa Benzinga

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Jan 19, 2021

08:14AM EST Alimera Sciences Sees Prelim. Q4 Sales Above $13.5M vs $13.43M Est., FY20 Sales Above $50.5M vs $50.49M Est. Benzinga

08:00AM EST Alimera Sciences Announces Preliminary Top-line Results for Fourth GlobeNewswire Inc

Jan 5, 2021

08:00AM EST Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021. GlobeNewswire Inc

Dec 9, 2020

08:38AM EST Alimera Subsidiary Launches ILUVIEN In The Netherlands RTTNews

08:34AM EST Alimera Sciences Reports Launch Of ILUVIEN In The Netherlands Benzinga

08:30AM EST Alimera Sciences Announces Launch of ILUVIEN in the GlobeNewswire Inc

Dec 8, 2020

08:30AM EST Alimera Sciences to Present at the 13th Annual LD Micro Main Event GlobeNewswire Inc

Nov 16, 2020

08:00AM EST Alimera Sciences Announces Participation at the 11th Annual GlobeNewswire Inc

Nov 12, 2020

08:12AM EST Alimera Sciences Highlights Clinical Data For ILUVIEN Will Be Presented At American Academy Of Ophthalmology Conference Nov. 13 Benzinga

08:00AM EST Alimera Sciences Announces Real-World Clinical Data for GlobeNewswire Inc

Nov 2, 2020

05:21PM EST Alimera Sciences S-3 Shows Registration For $100M Mixed Securities Shelf Offering Benzinga

Oct 28, 2020

04:44PM EDT Alimera Sciences Q3 EPS $(0.12) Beats $(0.44) Estimate, Sales $12.47M Beat $10.89M Estimate Benzinga

04:05PM EDT Alimera Sciences Announces Third Quarter 2020 Financial Results GlobeNewswire Inc

Oct 22, 2020

08:00AM EDT Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera or the Company), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces today that it will report third quarter 2020 financial results on Wednesday, October 28, 2020 after the market close. GlobeNewswire Inc

Sep 23, 2020

08:05AM EDT Alimera Sciences Announces Multiple Posters And Papers Highlighting Durability Of ILUVIEN To Be Presented At EURETINA 2020 Virtual Congress Benzinga

08:00AM EDT Alimera Sciences Announces Multiple Posters and Papers GlobeNewswire Inc

Sep 15, 2020

08:20AM EDT Alimera Sciences Signs Distribution Agreement With Medis Pharmaceutical To Commercialize Iluvien In Austria And Czech Republic Benzinga

08:00AM EDT Alimera Sciences Signs Distribution Agreement With Medis GlobeNewswire Inc

Sep 9, 2020

11:19AM EDT UPDATE -- Alimera Sciences Announces Participation at the H.C. GlobeNewswire Inc

08:00AM EDT Alimera Sciences Announces Participation at the H.C. Wainwright GlobeNewswire Inc

Sep 8, 2020

08:16AM EDT Alimera Sciences Obtains Reimbursement Approval For ILUVIEN Use In Non-Infectious Posterior Uveitis In Scotland Benzinga

08:00AM EDT Alimera Sciences Obtains Reimbursement Approval for GlobeNewswire Inc

Sep 1, 2020

08:18AM EDT Alimera Sciences Announces Enrollment Of First Patient In Landmark NEW DAY Clinical Trial To Evaluate ILUVIEN As Baseline Therapy For Diabetic Macular Edema Benzinga

08:00AM EDT Alimera Sciences Announces Enrollment of First Patient in Landmark GlobeNewswire Inc

Aug 26, 2020

08:32AM EDT Alimera Sciences Announces National Reimbursement Granted For ILUVIEN In The Netherlands Benzinga

08:30AM EDT Alimera Sciences Announces National Reimbursement Granted for GlobeNewswire Inc

Aug 25, 2020

08:00AM EDT Alimera Sciences to Present at the LD Micro 500 Virtual Conference GlobeNewswire Inc

Aug 13, 2020

08:17AM EDT Alimera Sciences Reports Distribution Deal With Nordic Prime To Expand Int'l. Sales OF ILUVIEN Into Nordic Countries Benzinga

08:15AM EDT Alimera Sciences Signs Distribution Agreement With Nordic Prime To Expand Sales Of ILUVIEN RTTNews

08:00AM EDT Alimera Sciences Signs Distribution Agreement With Nordic Prime to GlobeNewswire Inc

Jul 29, 2020

05:32PM EDT Recap: Alimera Sciences Q2 Earnings Benzinga

04:05PM EDT Alimera Sciences Announces Second Quarter 2020 Financial Results GlobeNewswire Inc

04:04AM EDT Earnings Scheduled For July 29, 2020 Benzinga

Jul 22, 2020

08:00AM EDT Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will report second quarter 2020 financial results on Wednesday, July 29, 2020 after the market close. GlobeNewswire Inc

Share